Hosted on MSN24d
AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)
AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of ...
Pharm Exec1mon
FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...
FiercePharma1mon
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
The FDA approval covers Emblaveo to be used in combination with the antibiotic metronidazole for patients with cIAIs who have limited or no other options. Emblaveo can be used to treat Gram ...
WebMD1mon
FDA OKs New Antibiotic Combo for Serious Abdominal Infections
Feb. 10, 2025 -- The FDA has approved a new antibiotic combination called Emblaveo to treat serious infections of the abdomen in adults who have few or no other treatment options. It will be ...
Crain's Chicago Business1mon
AbbVie gets FDA OK on antibiotic therapy that fights resistant bacteria
Emblaveo (aztreonam and avibactam ... for the treatment of complicated intra-abdominal infections (cIAI). The FDA granted Emblaveotm Qualified Infectious Disease Product Designation, and Fast ...
Renal & Urology News27d
Emblaveo Approved for Intra-Abdominal Infections in Patients With Limited Options
The Food and Drug Administration (FDA) has approved Emblaveoâ„¢ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative ...
pharmaphorum3d
FDA clears new antibiotic for superbug infections
AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...
PMLiVE1mon
AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo (aztreonam-avibactam) to treat complicated intra-abdominal infections, including those ...
MedCity News18d
On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval
Emblaveo was developed in partnership with Pfizer ... antibiotic’s commercialization in the rest of the world. — The FDA sent Harmony Biosciences a refuse to file letter for pitolistant ...
AbbVie (NYSE:ABBV) Expands SKYRIZI Availability In Canada For Ulcerative Colitis Treatment
AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...
clinicaladvisor.com1mon
Emblaveo Approved for Intra-Abdominal Infections in Patients With Limited Options
Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam ...